NASDAQ:ALT Altimmune (ALT) Stock Price, News & Analysis → The only AI company you should be looking at (From Behind the Markets) (Ad) Free ALT Stock Alerts $9.08 -0.78 (-7.91%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$9.04▼$9.7550-Day Range$8.22▼$13.8152-Week Range$2.09▼$14.84Volume4.01 million shsAverage Volume6.32 million shsMarket Capitalization$487.87 millionP/E RatioN/ADividend YieldN/APrice Target$15.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Altimmune alerts: Email Address Altimmune MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside73.5% Upside$15.75 Price TargetShort InterestHealthy20.12% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 13 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.43) to ($1.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.44 out of 5 starsMedical Sector548th out of 947 stocksPharmaceutical Preparations Industry255th out of 435 stocks 3.4 Analyst's Opinion Consensus RatingAltimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.75, Altimmune has a forecasted upside of 73.5% from its current price of $9.08.Amount of Analyst CoverageAltimmune has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted20.12% of the outstanding shares of Altimmune have been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Altimmune has recently decreased by 6.41%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAltimmune does not currently pay a dividend.Dividend GrowthAltimmune does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALT. Previous Next 3.2 News and Social Media Coverage News SentimentAltimmune has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Altimmune this week, compared to 3 articles on an average week.Search Interest96 people have searched for ALT on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows19 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is an increase of 111% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Altimmune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Altimmune is held by insiders.Percentage Held by Institutions66.99% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Altimmune are expected to decrease in the coming year, from ($1.43) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Altimmune is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Altimmune is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAltimmune has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Altimmune Stock (NASDAQ:ALT)Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Read More ALT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALT Stock News HeadlinesMarch 18, 2024 | finance.yahoo.comA Groundbreaking Milestone in the Treatment of NASH and Liver Fibrosis - AnerveaMarch 18, 2024 | seekingalpha.comShaping The Future Of Obesity Treatment: GLP-1 Agonists At The ForefrontMarch 18, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 17, 2024 | americanbankingnews.comAltimmune (NASDAQ:ALT) Shares Gap Up to $10.02March 15, 2024 | msn.comMadrigal Stock Soars 12% After FDA Approved The First MASH TreatmentMarch 15, 2024 | msn.comMadrigal Stock Soars 20% After FDA Approved The First MASH TreatmentMarch 15, 2024 | fool.comAltimmune (NASDAQ: ALT)March 14, 2024 | americanbankingnews.comAltimmune (NASDAQ:ALT) Trading Up 6.3%March 18, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 13, 2024 | seekingalpha.comUroGen Pharma Q4 2023 Earnings PreviewMarch 13, 2024 | finance.yahoo.comBMO Hosts First Obesity Summit on Future of Obesity Care MarketMarch 5, 2024 | prnewswire.comROSEN, A LONGSTANDING LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALTMarch 5, 2024 | msn.comAltimmune Stock (NASDAQ:ALT) Rides Volatility Wave Despite Promising PipelineMarch 3, 2024 | theglobeandmail.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALTMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALTFebruary 28, 2024 | benzinga.comHere's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth TodayFebruary 28, 2024 | theglobeandmail.comALT LOSS ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALTFebruary 28, 2024 | morningstar.comThinking about buying stock in Intuitive Machines, SoundHound AI, Interactive Strength, Altimmune, or NanoVibronix?February 27, 2024 | seekingalpha.comAltimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent RallyFebruary 27, 2024 | finance.yahoo.comLLY Apr 2024 665.000 putFebruary 26, 2024 | ca.finance.yahoo.comLLY Mar 2024 900.000 putFebruary 26, 2024 | msn.comAltimmune Stock Surges, Kerrisdale Remains Short: What You Need To KnowFebruary 26, 2024 | investors.comBiotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The ArenaFebruary 26, 2024 | investorplace.comWhy Is Altimmune (ALT) Stock Up 14% Today?February 26, 2024 | businesswire.comAltimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsFebruary 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALTFebruary 23, 2024 | stockhouse.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALTSee More Headlines Receive ALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today3/18/2024Next Earnings (Estimated)3/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALT CUSIPN/A CIK1326190 Webaltimmune.com Phone(240) 654-1450Fax410-269-2601Employees52Year FoundedN/APrice Target and Rating Average Stock Price Target$15.75 High Stock Price Target$20.00 Low Stock Price Target$13.00 Potential Upside/Downside+69.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-84,710,000.00 Net MarginsN/A Pretax Margin-28,124.01% Return on Equity-46.81% Return on Assets-42.23% Debt Debt-to-Equity RatioN/A Current Ratio12.89 Quick Ratio12.89 Sales & Book Value Annual Sales$4.41 million Price / Sales113.19 Cash FlowN/A Price / Cash FlowN/A Book Value$3.77 per share Price / Book2.46Miscellaneous Outstanding Shares53,730,000Free Float51,526,000Market Cap$499.15 million OptionableOptionable Beta0.08 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Vipin K. Garg Ph.D. (Age 66)President, CEO & Director Comp: $916.16kMr. Richard I. Eisenstadt M.B.A. (Age 66)Chief Financial Officer Comp: $619.69kDr. M. Scot Roberts Ph.D. (Age 65)Chief Scientific Officer Comp: $599.25kDr. Matthew Scott Harris AGAF (Age 71)FCAP, M.D., MS, Chief Medical Officer Comp: $643.04kMr. Bertrand Georges Ph.D.Chief Technology OfficerMr. Tony Blandin B.S.Vice President of Quality & Compliance ManagementMr. Raymond M. Jordt M.B.A. (Age 51)Chief Business Officer Mr. Andrew Shutterly M.S.Corporate ControllerMore ExecutivesKey CompetitorsIGM BiosciencesNASDAQ:IGMSTravere TherapeuticsNASDAQ:TVTXBiomea FusionNASDAQ:BMEAArriVent BioPharmaNASDAQ:AVBPRevance TherapeuticsNASDAQ:RVNCView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 227,677 shares on 3/11/2024Ownership: 6.648%Gerber LLCBought 255,778 shares on 3/5/2024Ownership: 0.476%American International Group Inc.Bought 1,599 shares on 2/28/2024Ownership: 0.049%GSA Capital Partners LLPSold 236,406 shares on 2/16/2024Ownership: 0.390%Price T Rowe Associates Inc. MDBought 3,370 shares on 2/16/2024Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions ALT Stock Analysis - Frequently Asked Questions Should I buy or sell Altimmune stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALT shares. View ALT analyst ratings or view top-rated stocks. What is Altimmune's stock price target for 2024? 4 brokers have issued twelve-month price objectives for Altimmune's stock. Their ALT share price targets range from $13.00 to $20.00. On average, they anticipate the company's share price to reach $15.75 in the next twelve months. This suggests a possible upside of 73.5% from the stock's current price. View analysts price targets for ALT or view top-rated stocks among Wall Street analysts. How have ALT shares performed in 2024? Altimmune's stock was trading at $11.25 at the beginning of 2024. Since then, ALT shares have decreased by 19.3% and is now trading at $9.08. View the best growth stocks for 2024 here. Are investors shorting Altimmune? Altimmune saw a decline in short interest in February. As of February 29th, there was short interest totaling 10,810,000 shares, a decline of 6.4% from the February 14th total of 11,550,000 shares. Based on an average daily trading volume, of 9,860,000 shares, the days-to-cover ratio is presently 1.1 days. View Altimmune's Short Interest. When is Altimmune's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024. View our ALT earnings forecast. How were Altimmune's earnings last quarter? Altimmune, Inc. (NASDAQ:ALT) released its quarterly earnings data on Monday, November, 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.45. The company had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.11 million. During the same period in the previous year, the company posted ($0.54) earnings per share. When did Altimmune's stock split? Altimmune's stock reverse split before market open on Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Altimmune own? Based on aggregate information from My MarketBeat watchlists, some companies that other Altimmune investors own include Vaxart (VXRT), Pfizer (PFE), Verizon Communications (VZ), Amarin (AMRN), Advanced Micro Devices (AMD), Albireo Pharma (ALBO), Alliance Data Systems (ADS), AcelRx Pharmaceuticals (ACRX), Albertsons Companies (ACI) and Achieve Life Sciences (ACHV). Who are Altimmune's major shareholders? Altimmune's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.65%), Vanguard Group Inc. (6.65%), Nuveen Asset Management LLC (3.21%), Point72 Asset Management L.P. (2.32%), Timelo Investment Management Inc. (1.51%) and Goldman Sachs Group Inc. (0.98%). Insiders that own company stock include David Drutz, Diane Jorkasky, M Scot Roberts, Matthew Scott Harris, Vipin K Garg and Wayne Pisano. View institutional ownership trends. How do I buy shares of Altimmune? Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALT) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.